Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to ...

The daily medication, called hydromethylthionine mesylate (HMTM), was developed by British firm TauRX in Aberdeen ...

SCIENTISTS investigating Alzheimer’s disease have made a key breakthrough, identifying a key cellular process that drives ...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Pepinemab is under clinical development by Vaccinex and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease.

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

Alzheimer's is the most common cause of dementia and researchers say their findings could lead to treatments that could slow ...

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

In a new discovery in the battle against Alzheimer's disease, scientists have pinpointed a key cellular mechanism that is the ...